Is the Dosing and Timing of the Intervention Adequate?

  • A. F. Suffredini
Conference paper


During the last decade, major advances have been made in defining mechanisms of shock and organ injury due to infection. Intact host inflammatory responses are critical to limit and resolve serious infections. However, when these responses are intense they contribute to tissue injury and organ failure. Attempts to suppress inflammatory responses using corticosteroids or mediator-specific antagonists (e.g. tumor necrosis factor (TNF) antibodies) have either not improved survival or have been harmful in septic patients with life-threatening infections [13]. The rationale for the use of anti-inflammatory agents in sepsis seems well founded. The proinflammatory cytokines TNF and IL-1 are detected during infections and when administered to humans or animals result in manifestations of shock. In some animal models, antagonists to TNF or IL-1 protect them from lethal bacterial challenge [4] . However, the inability to translate these observations into clinical use has led to a reassessment of this therapeutic approach.


Tumor Necrosis Factor Septic Shock Soluble Tumor Necrosis Factor Receptor Sepsis Trial Plasma Tumor Necrosis Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095–1100PubMedCrossRefGoogle Scholar
  2. 2.
    Bone RC, Fisher CJ Jr, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher CJ Jr, Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697–1702PubMedCrossRefGoogle Scholar
  4. 4.
    Natanson C, Hoffman WD, Suffredini AF et al (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771–783PubMedGoogle Scholar
  5. 5.
    Cronin L, Cook DJ, Carlet J et al (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439PubMedCrossRefGoogle Scholar
  6. 6.
    Lefering R, Neugebauer EA (1995) Steroid controversy in sepsis and septic shock: a metaanalysis. Crit Care Med 23:1294–1303PubMedCrossRefGoogle Scholar
  7. 7.
    Natanson C, Esposito CJ, Banks SM (1998) The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26:1927–1931PubMedCrossRefGoogle Scholar
  8. 8.
    Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147PubMedCrossRefGoogle Scholar
  9. 9.
    Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405PubMedCrossRefGoogle Scholar
  10. 10.
    Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871PubMedCrossRefGoogle Scholar
  11. 11.
    Eichacker PQ (1997) The relevance of animal models in sepsis. In: The Second International Symposium on Infections in the Critically Ill Patient. Feb 14, Barcelona, SpainGoogle Scholar
  12. 12.
    The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665CrossRefGoogle Scholar
  13. 13.
    Abraham E, Wunderink R, Silverman H et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 273:934–941PubMedCrossRefGoogle Scholar
  14. 14.
    Abraham E, Anzueto A, Gutierrez G et al (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Norasept II Study Group. Lancet 351:929–933PubMedGoogle Scholar
  15. 15.
    Rolan P (1997) The contribution of clinical pharmacology surrogates and models to drug development — a critical appraisal. Br J Clin Pharmacol 44:219–225PubMedCrossRefGoogle Scholar
  16. 16.
    Goldie AS, Fearon KC, Ross JA et al (1995) Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 274:172–177PubMedCrossRefGoogle Scholar
  17. 17.
    Reinhart K, Wiegand-Lohnert C, Grimminger F et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, doseranging study. Crit Care Med 24:733–742PubMedCrossRefGoogle Scholar
  18. 18.
    Abraham E, Glauser MP, Butler T et al (1997) p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45–2081 Study Group. JAMA 277:1531–1538PubMedCrossRefGoogle Scholar
  19. 19.
    Kay C (1996) Can better measures of cytokine responses be obtained to guide cytokine inhibition? In: Institutes’ CH (ed) Designing Better Drugs and Clinical Trials for Sepsis/SIRS: Reducing Mortality to Patients and Suppliers. Feb 20–21, Washington, DCGoogle Scholar
  20. 20.
    Suffredini AF, Reda D, Banks SM et al (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038–5045PubMedGoogle Scholar
  21. 21.
    Preas HL, Reda D, Tropea M et al (1996) Effects of recombinant soluble type I IL-1 receptor on human inflammatory responses to endotoxin. Blood 88:2465–2472PubMedGoogle Scholar
  22. 22.
    Bollaert PE, Charpentier C, Levy B et al (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645–650PubMedCrossRefGoogle Scholar
  23. 23.
    Briegel J, Forst H, Haller M et al (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single center study. Crit Care Med 27:723–732PubMedCrossRefGoogle Scholar
  24. 24.
    Chawla K, Kupfer Y, Goldman I, Tessler S (1999) Hydrocortisone reverses refractory septic shock (abstract). Crit Care Med 27[Suppl]:A33CrossRefGoogle Scholar
  25. 25.
    Meduri GU, Kanangat S (1998) Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med 26:630–633PubMedCrossRefGoogle Scholar
  26. 26.
    Parent C, Natanson C, Cui X et al (1999) Control mortality and exclusion criteria: factors potentially altering the effects of anti-inflammatory therapies in clinical sepsis. Am J Resp Crit Care Med 159:A263Google Scholar
  27. 27.
    Brandtzaeg P, Osnes L, Ovstebo R et al (1996) Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin10 as a major functional deactivator of human monocytes. J Exp Med 184:51–60PubMedCrossRefGoogle Scholar
  28. 28.
    Nylen ES, Whang KT, Snider RH Jr et al (1998) Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 26:1001–1006PubMedCrossRefGoogle Scholar
  29. 29.
    Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251PubMedCrossRefGoogle Scholar
  30. 30.
    The Chipping Forecast (1999) Nature Genetics January:1–60Google Scholar
  31. 31.
    Iyer VR, Eisen MB, Ross DT et al (1999) The transcriptional program in the response of human fibroblasts to serum. Science 283:83–87PubMedCrossRefGoogle Scholar
  32. 32.
    Ramsay G (1998) DNA chips: state-of-the art. Nat Biotechnol 16:40–44PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • A. F. Suffredini

There are no affiliations available

Personalised recommendations